Francois Boue

Gif-sur-yvette, FR 
Gif-sur-yvette, FR 

Overview

Francois Boue practices practicing medicine in Gif-sur-yvette, France.

His clinical expertise encompasses Kaposi Sarcoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Hepatitis C.

He is actively involved in clinical research, co-authoring 47 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Gif-sur-yvette, 91191, France
Other Locations
Clamart, France
Paris, France
Saclay, France
Thiverval-grignon, 78850, France
CEA Saclay, France. And Manufacture Française Des Pneumatiques MICHELIN, 23 Place Des Carmes Déchaux, F-63 040 Clermont Ferrand, Cedex 9, Clermont-ferrand, 91191, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Vinblastine
Study Phase: Phase 1/Phase 2
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: Romidepsin, CHOP
Study Phase: Phase 3
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Brentuximab
Study Phase: Phase 2
Prevention of HIV in Île-de-France
Prevention of HIV in Île-de-France
Enrollment Status: Unknown
Publish Date: June 02, 2022
Intervention Type: Drug
Study Phase: Not Applicable
Evaluation of a Shared Health Information System for Home-hospital Management of Febrile NEUTROpenia After Cytotoxic Chemotherapy
Evaluation of a Shared Health Information System for Home-hospital Management of Febrile NEUTROpenia After Cytotoxic Chemotherapy
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Device
Study Phase: Not Applicable
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

47 Total Publications

Design of ultra-stretchable physical hydrogels cross-linked by cubosomes: structural changes revealed by SANS during in situ polymerisation and mechanical deformation.
Design of ultra-stretchable physical hydrogels cross-linked by cubosomes: structural changes revealed by SANS during in situ polymerisation and mechanical deformation.
Journal: Soft matter
Published: June 05, 2025

Frequently Asked Questions about Francois Boue

Is Francois Boue a top-rated expert for Kaposi Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Francois Boue is classified as an Experienced expert for Kaposi Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Francois Boue participate in research or clinical trials?

Yes. Francois Boue has published 47 articles and abstracts on conditions like Kaposi Sarcoma. You can view a list of Francois Boue's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Boue's expertise for a condition
ConditionClose
        View All 9 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile